WO2005082331A3 - Extended release tablets of clarithromycin - Google Patents

Extended release tablets of clarithromycin Download PDF

Info

Publication number
WO2005082331A3
WO2005082331A3 PCT/IB2005/000502 IB2005000502W WO2005082331A3 WO 2005082331 A3 WO2005082331 A3 WO 2005082331A3 IB 2005000502 W IB2005000502 W IB 2005000502W WO 2005082331 A3 WO2005082331 A3 WO 2005082331A3
Authority
WO
WIPO (PCT)
Prior art keywords
clarithromycin
extended release
release tablets
pharmaceutically acceptable
acceptable carrier
Prior art date
Application number
PCT/IB2005/000502
Other languages
French (fr)
Other versions
WO2005082331A2 (en
Inventor
Prashant Manohar Mandaogade
Rajeev Singh Raghuvanshi
Ashok Rampal
Original Assignee
Ranbaxy Lab Ltd
Prashant Manohar Mandaogade
Rajeev Singh Raghuvanshi
Ashok Rampal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IN306DE2004 external-priority patent/IN2004DE00306A/en
Application filed by Ranbaxy Lab Ltd, Prashant Manohar Mandaogade, Rajeev Singh Raghuvanshi, Ashok Rampal filed Critical Ranbaxy Lab Ltd
Priority to EP05708615A priority Critical patent/EP1720524A2/en
Publication of WO2005082331A2 publication Critical patent/WO2005082331A2/en
Publication of WO2005082331A3 publication Critical patent/WO2005082331A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

The present invention relates to extended release tablets for oral administration comprising clarithromycin and a pharmaceutically acceptable carrier, wherin the pharmaceutically acceptable carrier comprises a mixture of lactose and microcrysalline cellulose in a ration ranging from 3:1 to 1:3, and processes for their preparation.
PCT/IB2005/000502 2004-02-26 2005-02-25 Extended release tablets of clarithromycin WO2005082331A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05708615A EP1720524A2 (en) 2004-02-26 2005-02-25 Extended release tablets of clarithromycin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN306/DEL/2004 2004-02-26
IN306DE2004 IN2004DE00306A (en) 2001-08-22 2004-02-26

Publications (2)

Publication Number Publication Date
WO2005082331A2 WO2005082331A2 (en) 2005-09-09
WO2005082331A3 true WO2005082331A3 (en) 2006-03-30

Family

ID=34897732

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/000502 WO2005082331A2 (en) 2004-02-26 2005-02-25 Extended release tablets of clarithromycin

Country Status (2)

Country Link
EP (1) EP1720524A2 (en)
WO (1) WO2005082331A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1803450A1 (en) 2006-01-03 2007-07-04 Ferrer Internacional, S.A. Pharmaceutical compositions for the eradication of helicobacter pylori
CN100438917C (en) * 2006-07-20 2008-12-03 山东聊城阿华制药有限公司 Process for preparing micro crystal cellulose milk sugar
WO2008114143A1 (en) * 2007-03-22 2008-09-25 Aurobindo Pharma Limited Extended release formulations of macrolide antibiotic
DE102008047910A1 (en) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tabletting excipient based on lactose and cellulose
EP2671571A1 (en) * 2012-06-05 2013-12-11 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-release formulations of clarithromycin

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049246A2 (en) * 2000-01-05 2001-07-12 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Sustained release tablet formulations comprising clarithromycin
US20020150619A1 (en) * 2000-02-24 2002-10-17 Rudnic Edward M. Erythromyacin antibiotic product, use and formulation thereof
US20030077323A1 (en) * 2000-02-24 2003-04-24 Rudnic Edward M. Amoxicillin - clarithromycin antibiotic composition
US20030104055A1 (en) * 2000-02-24 2003-06-05 Rudnic Edward M. Antibiotic product, use and formulation thereof
WO2004087112A1 (en) * 2003-03-31 2004-10-14 Korea United Pharm, Inc. Manufacturing method and formulation for bitter taste masked oral dosage form of clarithromycin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049246A2 (en) * 2000-01-05 2001-07-12 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Sustained release tablet formulations comprising clarithromycin
US20020150619A1 (en) * 2000-02-24 2002-10-17 Rudnic Edward M. Erythromyacin antibiotic product, use and formulation thereof
US20030077323A1 (en) * 2000-02-24 2003-04-24 Rudnic Edward M. Amoxicillin - clarithromycin antibiotic composition
US20030104055A1 (en) * 2000-02-24 2003-06-05 Rudnic Edward M. Antibiotic product, use and formulation thereof
WO2004087112A1 (en) * 2003-03-31 2004-10-14 Korea United Pharm, Inc. Manufacturing method and formulation for bitter taste masked oral dosage form of clarithromycin

Also Published As

Publication number Publication date
EP1720524A2 (en) 2006-11-15
WO2005082331A2 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
AU2003229555A1 (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
WO2004069198A3 (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
WO2004043430A3 (en) Botulinum toxin formulations for oral administration
WO2008027557A3 (en) Topiramate compositions and methods of enhancing its bioavailability
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
WO2008061226A3 (en) Sustained-release formulations of topiramate
WO2006102446A3 (en) Multi-particulate, modified-released colonic composition
WO2001032183A3 (en) Pharmaceutical compositions comprising oxcarbazepine
YU58103A (en) Pharmaceutical dosage forms of epothilones for oral administration
EP2008650A3 (en) Solid oral composition comprising a S 1 P receptor agonist and a sugar alcohol
WO2005065318A3 (en) Effervescent oral opiate dosage form
MXPA02003596A (en) Novel pharmaceutical compositions of anti-tubercular drugs and process for their preparation.
WO2007144169A3 (en) Entacapone-derivatives
CA2431565A1 (en) Pharmaceutical compositions based on anticholinergics and ciclesonide
WO2002094774A3 (en) Oxcarbazepine dosage forms
WO2002017885A3 (en) Controlled release formulation of erythromycin or a derivative thereof
HRP20010632A2 (en) Matrix tablet enabling prolonged release of gliclazide after administration by the oral route
WO2007142810A3 (en) Methods of using low-dose doxepin for the improvement of sleep
PL348419A1 (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
WO2002024203A3 (en) Controlled release formulations for oral administration
HRPK20010706B1 (en) Tolperison-containing, pharmaceutical preparation for oral administration
WO2005082331A3 (en) Extended release tablets of clarithromycin
WO2006113647A3 (en) Recovery of tissue function following administration of b cells to injured tissue
WO2007123883A3 (en) Oral dosage formulations and methods of preparing the same
WO2005004860A3 (en) Novel solid pharmaceutical composition comprising amisulpride

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005708615

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 5076/DELNP/2006

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2005708615

Country of ref document: EP